Renal function during ticrynafen therapy.
526 patients with essential hypertension or congestive cardiac failure were treated with ticrynafen (250--500 mg/day) or hydrochlorothiazide (50--100 mg/day) for 6 weeks to 6 months. There was no appreciable effect on renal function, as measured by changes in blood urea nitrogen and serum creatinine levels. Both drugs exhibited similar antihypertensive activity and ability to control signs and symptoms of congestive cardiac failure. Side effects were mild and reversible. A notable difference is the marked reduction in serum uric acid in patients treated with ticrynafen, unlike the elevated urate levels occurring after treatment with hydrochlorothiazide.
D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000494:pharmacology / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006852:Hydrochlorothiazide / Q000494:pharmacology / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D007668:Kidney / Q000187:drug effects; D010642:Phenoxyacetates / Q000494:pharmacology / Q000627:therapeutic use; D014528:Uricosuric Agents / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D004232:Diuretics; D010642:Phenoxyacetates; D014528:Uricosuric Agents; D006852:Hydrochlorothiazide